Stocktoria
Celcuity Inc. CELC
Celcuity Inc. (CELC) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-03 | Craig-Hallum | Buy (main) |
| 2026-06-03 | Wells Fargo | Overweight (main) |
| 2026-06-03 | HC Wainwright & Co. | Buy (main) |
| 2026-05-18 | HC Wainwright & Co. | Buy (main) |
| 2026-05-15 | Wells Fargo | Overweight (main) |
| 2026-05-15 | Needham | Buy (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.903 |
| Retained earnings / assets | -0.962 |
| EBIT / assets | -0.369 |
| Equity / liabilities | 0.275 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CELC | Celcuity Inc. | 4/9 | 0.6 | — | — |
| LH | LABCORP HOLDINGS INC. | 8/9 | 3.39 | 25.4 | +7.2% |
| DGX | QUEST DIAGNOSTICS INC | 7/9 | 3.53 | 23.4 | +11.8% |
| FTRE | Fortrea Holdings Inc. | 3/9 | -3.58 | — | +1% |
| NTRA | Natera, Inc. | 3/9 | 0.87 | — | +35.9% |
| RDNT | RadNet, Inc. | 3/9 | 1.4 | — | +11.5% |
| GH | Guardant Health, Inc. | 4/9 | -2.57 | — | +32.9% |
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
FAQ
Is CELC financially healthy?
Celcuity Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CELC pay a dividend?
No, Celcuity Inc. does not currently pay a dividend.
How profitable is CELC?
In FY2025, Celcuity Inc. had a return on equity of -176.1%.
What is the analyst price target for CELC?
The average Wall-Street price target for Celcuity Inc. is $160.64, about 74.5% above the recent price, from 11 analysts (consensus: strong buy).
Is CELC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Celcuity Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.